ADC Therapeutics (ADCT) Current Assets (2019 - 2026)

ADC Therapeutics (ADCT) has reported Current Assets for 8 consecutive years, with $276.8 million the latest figure, recorded in Q1 2026.

• Quarterly Current Assets rose 7.28% year-over-year to $276.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.8 million (up 7.28% YoY) and the FY2025 annual result came in at $306.3 million, up 5.18% from the prior year.
• Current Assets slipped to $276.8 million in Q1 2026 per ADCT's latest filing, from $306.3 million in the prior quarter.
• Over the last five years, Current Assets for ADCT reached as high as $487.7 million in Q1 2022 and fell as low as $258.0 million in Q1 2025.
• A 5-year average of $353.3 million and a median of $336.3 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets increased 24.02% — and 2024, when it dropped 23.63%.
• Year by year, Current Assets stood at $435.0 million in 2022, then declined by 22.69% to $336.3 million in 2023, then declined by 13.39% to $291.3 million in 2024, then rose by 5.18% to $306.3 million in 2025, then declined by 9.65% to $276.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $276.8 million, $306.3 million, and $287.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.